vs
Side-by-side financial comparison of Bio-Techne (TECH) and Yatsen Holding Ltd (YSG). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($311.4M vs $164.2M, roughly 1.9× Yatsen Holding Ltd). Bio-Techne runs the higher net margin — 16.4% vs -0.5%, a 16.9% gap on every dollar of revenue. Over the past eight quarters, Yatsen Holding Ltd's revenue compounded faster (24.5% CAGR vs 1.3%).
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
Yatsen Holding Ltd is a leading China-based beauty and personal care group. It develops and sells cosmetics, skincare products and fragrances under brands including Perfect Diary, Little Ondine and Abby's Choice, with core markets in mainland China, Southeast Asia, targeting Gen Z and young adult consumers.
TECH vs YSG — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $311.4M | $164.2M |
| Net Profit | $51.0M | $-776.5K |
| Gross Margin | 66.9% | 77.8% |
| Operating Margin | 24.2% | -34.0% |
| Net Margin | 16.4% | -0.5% |
| Revenue YoY | -1.5% | — |
| Net Profit YoY | 126.0% | — |
| EPS (diluted) | $0.32 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $311.4M | — | ||
| Q4 25 | $295.9M | $164.2M | ||
| Q3 25 | — | $95.1M | ||
| Q2 25 | $317.0M | $110.9M | ||
| Q1 25 | $316.2M | $106.6M | ||
| Q4 24 | $297.0M | $147.0M | ||
| Q3 24 | $289.5M | $102.3M | ||
| Q2 24 | $306.1M | $118.1M |
| Q1 26 | $51.0M | — | ||
| Q4 25 | $38.0M | $-776.5K | ||
| Q3 25 | — | $-17.0M | ||
| Q2 25 | $-17.7M | $-11.9M | ||
| Q1 25 | $22.6M | $-17.2M | ||
| Q4 24 | $34.9M | $-67.7M | ||
| Q3 24 | $33.6M | $-28.2M | ||
| Q2 24 | $40.6M | $-14.9M |
| Q1 26 | 66.9% | — | ||
| Q4 25 | 64.6% | 77.8% | ||
| Q3 25 | — | 75.9% | ||
| Q2 25 | 62.7% | 76.7% | ||
| Q1 25 | 67.9% | 77.7% | ||
| Q4 24 | 65.3% | 73.7% | ||
| Q3 24 | 63.2% | 71.4% | ||
| Q2 24 | 66.4% | 74.7% |
| Q1 26 | 24.2% | — | ||
| Q4 25 | 18.4% | -34.0% | ||
| Q3 25 | — | -20.9% | ||
| Q2 25 | -7.5% | -17.0% | ||
| Q1 25 | 12.2% | -20.4% | ||
| Q4 24 | 16.0% | -50.3% | ||
| Q3 24 | 13.8% | -32.2% | ||
| Q2 24 | 15.0% | -15.7% |
| Q1 26 | 16.4% | — | ||
| Q4 25 | 12.8% | -0.5% | ||
| Q3 25 | — | -17.9% | ||
| Q2 25 | -5.6% | -10.8% | ||
| Q1 25 | 7.1% | -16.1% | ||
| Q4 24 | 11.7% | -46.1% | ||
| Q3 24 | 11.6% | -27.6% | ||
| Q2 24 | 13.3% | -12.6% |
| Q1 26 | $0.32 | — | ||
| Q4 25 | $0.24 | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-0.11 | — | ||
| Q1 25 | $0.14 | — | ||
| Q4 24 | $0.22 | — | ||
| Q3 24 | $0.21 | — | ||
| Q2 24 | $0.26 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $209.8M | $109.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.1B | $428.9M |
| Total Assets | $2.6B | $550.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $209.8M | — | ||
| Q4 25 | $172.9M | $109.4M | ||
| Q3 25 | — | $97.0M | ||
| Q2 25 | $162.2M | $133.1M | ||
| Q1 25 | $140.7M | $92.3M | ||
| Q4 24 | $177.5M | $112.0M | ||
| Q3 24 | $187.5M | $71.7M | ||
| Q2 24 | $152.9M | $109.6M |
| Q1 26 | — | — | ||
| Q4 25 | $260.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $346.0M | — | ||
| Q1 25 | $330.0M | — | ||
| Q4 24 | $300.0M | — | ||
| Q3 24 | $300.0M | — | ||
| Q2 24 | $319.0M | — |
| Q1 26 | $2.1B | — | ||
| Q4 25 | $2.0B | $428.9M | ||
| Q3 25 | — | $423.1M | ||
| Q2 25 | $1.9B | $431.5M | ||
| Q1 25 | $2.0B | $422.2M | ||
| Q4 24 | $2.1B | $418.1M | ||
| Q3 24 | $2.1B | $516.0M | ||
| Q2 24 | $2.1B | $519.4M |
| Q1 26 | $2.6B | — | ||
| Q4 25 | $2.5B | $550.1M | ||
| Q3 25 | — | $564.8M | ||
| Q2 25 | $2.6B | $564.4M | ||
| Q1 25 | $2.6B | $534.3M | ||
| Q4 24 | $2.7B | $544.0M | ||
| Q3 24 | $2.7B | $635.6M | ||
| Q2 24 | $2.7B | $635.8M |
| Q1 26 | — | — | ||
| Q4 25 | 0.13× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.18× | — | ||
| Q1 25 | 0.16× | — | ||
| Q4 24 | 0.14× | — | ||
| Q3 24 | 0.14× | — | ||
| Q2 24 | 0.15× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
YSG
Segment breakdown not available.
